Holen Sie sich die Stockscreener-App
1.91
1.55%
-0.03
Schlusskurs vom Vortag:
$1.94
Offen:
$1.92
24-Stunden-Volumen:
72,722
Relative Volume:
0.03
Marktkapitalisierung:
$25.35M
Einnahmen:
$2.14M
Nettoeinkommen (Verlust:
$-15.44M
KGV:
-0.6172
EPS:
-3.0946
Netto-Cashflow:
$-24.67M
1W Leistung:
+1.60%
1M Leistung:
+2.14%
6M Leistung:
-52.01%
1J Leistung:
-94.00%
1-Tages-Spanne:
$1.87
$1.94
1-Wochen-Bereich:
$1.81
$1.9586
52-Wochen-Spanne:
$1.50
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
1.9001 | 25.88M | 2.14M | -15.44M | -24.67M | -3.0946 |
VRTX
Vertex Pharmaceuticals Inc
|
520.96 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,006.39 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.91 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.54 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-10-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-10-13 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Eingeleitet | Raymond James | Outperform |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Lucid Capital Markets initiates Tvardi stock with buy rating - Investing.com
Lucid Capital Markets initiates Tvardi stock with buy rating By Investing.com - Investing.com India
Tvardi stock falls as investors book gains after Phase 1 data - scanx.trade
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Barchart.com
Tvardi Therapeutics to Participate in Upcoming Investor Events - barchart.com
Tvardi (TVRD) Q1 2026 Results: The EPS Result Is Above Expectation in the Latest Reading; After Earnings: Shares Close 2.25% Higher in Latest TradingEarnings Whisper Number - vinanet.vn
Tvardi Therapeutics (TVRD) Receives a Hold from Cantor Fitzgerald - The Globe and Mail
Tvardi (TVRD) Shares: Finishes 2.66% Down at $1.83 on the Day; Current Setup: the Near-Term Reference Band Stretches From $1.74 to $1.92 on the DayFlat Correction - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
BTIG Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative ColitisSlideshow - Seeking Alpha
Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data - TradingView
Tvardi Therapeutics: TTI-109 targets STAT3 to address unmet needs in UC with selective immune modulation and safety - TradingView
Tvardi Therapeutics: TTI-109 offers targeted STAT3 inhibition with improved safety and efficacy for UC and HCC - TradingView
H.C. Wainwright reiterates Tvardi stock rating citing UC pivot - Investing.com
H.C. Wainwright reiterates Tvardi stock rating citing UC pivot By Investing.com - Investing.com UK
Tvardi Reports $6.5 Million Second-Quarter Net Loss and TTI-109 UC Plans - Moomoo
Tvardi Therapeutics increases ATM offering to $9.69M - scanx.trade
Tvardi Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Tvardi Q2 net loss reaches $6.5 million - grafa.com
H.C. Wainwright Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Tvardi Therapeutics Reports Q2 2026 Net Loss of $6.5 Million - Minichart
Tvardi Therapeutics | 8-K: Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - Moomoo
Tvardi Q2 EPS $(0.69) beats $(0.70) estimate, loss narrows 31% - scanx.trade
Form 8K Tvardi Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Tvardi Therapeutics, Inc. 2026: Revenue ($6.46M), EPS ($0.69) — 10-Q Summary - TradingView
Tvardi Reports Positive TTI-109 Data, Picks Ulcerative Colitis for Next-Gen Drug - Minichart
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - The Manila Times
Tvardi Therapeutics: Q2 2026 saw a $6.5M net loss, cash of $15.8M, and urgent need for additional funding - TradingView
Tvardi posts Q2 2026 net loss of $6.5M, cash $15.8M; reports TTI-109 healthy volunteer topline - TradingView
Tvardi Therapeutics Reports Topline Healthy Volunteer Results for TTI-109 and Selects Ulcerative Colitis as Initial Indication - Quiver Quantitative
Tvardi Therapeutics: TTI-109 advanced for UC after positive topline results; Q2 net loss was $6.5 million - TradingView
Tvardi: Q2 Earnings Snapshot - KTVB
BRIEF-Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million - TradingView
Tvardi Therapeutics (TVRD) Holds Ground at $1.77 Amid Cautious Biotech SentimentBullish Pattern Stocks - Vinanet
Tvardi Therapeutics to Host KOL Webinar on the Clinical - GlobeNewswire
JonesTrading Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Tvardi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – FWB:69C - TradingView
Raymond James upgrades Tvardi Therapeutics stock rating on Phase 1 data - Investing.com Nigeria
TVRD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Tvardi Therapeutics Ord Shs (TVRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial - Quiver Quantitative
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 - GlobeNewswire
Tvardi Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Pipeline ProgressEarnings Manipulation Risk - dars.gov.et
TVRD|Tvardi Therapeutics Ord Shs|Price:2.555|Chg%:+0.045 - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Institutional Confidence - TradingKey
Tvardi Therapeutics (TVRD) Edges Higher, Testing Key Resistance LevelsCall Flow Alert - vinanet.vn
Tvardi Therapeutics Inc. Revenue Breakdown – LS:A414VY - TradingView
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):